Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable ...

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 ...

Eli Lilly's GLP-1 franchise, anchored by Mounjaro and Zepbound, is reinforced by upcoming oral and next-gen injectable ...

Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch ...

The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

Infectious disease could fuel Eli Lilly's next growth phase.

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with ...

Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become ...